Forest Laboratories, Inc. (FRX) Tops Q4 EPS by 1c, Sales Miss Views
Tweet
Share
E-mailGet Alerts FRX Hot Sheet
Price: $12.00 --0%
Financial Fact:
Selling, general and administrative: 678.82M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Selling, general and administrative: 678.82M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Forest Laboratories, Inc. (NYSE: FRX) reported Q4 EPS of $0.17, $0.01 better than the analyst estimate of $0.16. Revenue for the quarter came in at $783.2 million versus the consensus estimate of $807 million and $996.9 million in the prior year quarter. The decrease in sales was due to the loss of patent exclusivity on March 14, 2012 for Lexapro® (escitalopram oxalate), partially offset by sales of the Company’s next generation products.
Forest Laboratories, Inc. sees FY2013 EPS of $0.80-1.00, versus the consensus of $0.95.
For earnings history and earnings-related data on Forest Laboratories, Inc. (FRX) click here.
Forest Laboratories, Inc. sees FY2013 EPS of $0.80-1.00, versus the consensus of $0.95.
For earnings history and earnings-related data on Forest Laboratories, Inc. (FRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Investing.com’s stocks of the week
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
